Fused heterocyclic derivatives as S1P modulators

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 8796262
APP PUB NO 20130203737A1
SERIAL NO

13808908

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

This invention relates to new fused heterocyclic derivatives having affinity to S1P receptors, a pharmaceutical composition containing said compounds, as well as the use of said compounds for the preparation of a medicament for treating, alleviating or preventing diseases and conditions in which any S1P receptor is involved or in which modulation of the endogenous S1P signaling system via any S1P receptor is involved.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

  • ABBVIE B.V.;ABBVIE INC.

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Coolen, Hein K A C Hoofddorp, NL 17 26
den, Hartog Jacobus A J Hoofddorp, NL 17 37
Hobson, Adrian Worcester, US 11 26
Iwema, Bakker Wouter I Hoofddorp, NL 21 59
Sliedregt, Leonardus A J M Hoofddorp, NL 4 7
Smid, Pieter Hoofddorp, NL 10 17
van, Dongen Maria J P Hoofddorp, NL 8 16

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 Feb 5, 2026
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00